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Abstract
Background: We previously showed that a VLDL- and LDL-rich mix of human native lipoproteins induces a set of
repressive epigenetic marks, i.e. de novo DNA methylation, histone 4 hypoacetylation and histone 4 lysine 20
(H4K20) hypermethylation in THP-1 macrophages. Here, we: 1) ask what gene expression changes accompany
these epigenetic responses; 2) test the involvement of candidate factors mediating the latter. We exploited
genome expression arrays to identify target genes for lipoprotein-induced silencing, in addition to RNAi and
expression studies to test the involvement of candidate mediating factors. The study was conducted in human
THP-1 macrophages.
Results: Native lipoprotein-induced de novo DNA methylation was associated with a general repression of various
critical genes for macrophage function, including pro-inflammatory genes. Lipoproteins showed differential effects
on epigenetic marks, as de novo DNA methylation was induced by VLDL and to a lesser extent by LDL, but not by
HDL, and VLDL induced H4K20 hypermethylation, while HDL caused H4 deacetylation. The analysis of candidate
factors mediating VLDL-induced DNA hypermethylation revealed that this response was: 1) surprisingly, mediated
exclusively by the canonical maintenance DNA methyltransferase DNMT1, and 2) independent of the Dicer/micro-
RNA pathway.
Conclusions: Our work provides novel insights into epigenetic gene regulation by native lipoproteins.
Furthermore, we provide an example of DNMT1 acting as a de novo DNA methyltransferase independently of
canonical de novo enzymes, and show proof of principle that de novo DNA methylation can occur independently
of a functional Dicer/micro-RNA pathway in mammals.
Background
Atherosclerosis is characterised by the accumulation of
lipids, extracellular matrix, smooth muscle, inflammatory
and immune cells in the arterial wall [1]. Diet-related and
environment-related factors are pivotal determinants of
atherosclerosis risk, thus epigenome remodelling by such
factors has been proposed as an important underlying
molecular mechanism for that disease [2]. According to
this view, environmental and nutritional risk factors might
impose stable epigenetic “hits” during an individual’s
lifetime that, possibly in synergy with other concomitant
molecular changes, cause anti- or pro-atherogenic gene
expression patterns [3,4]. Indeed, altered DNA methyla-
tion patterns have been detected in atherosclerosis [5-7].
Such changes may at least in part be caused by abnormal
lipoprotein profiles, given their central role in atherogen-
esis [1]. This idea is supported by our previous observation
that a very low density- and low density lipoprotein
(VLDL and LDL, respectively)-rich lipoprotein mix (VLR)
induces global de novo DNA methylation in THP-1
human macrophages, in addition to other epigenetic mod-
ifications associated with non-permissive chromatin. The
latter include loss of histone 4 acetylation and an increase
in histone 4 lysine 20 hypermethylation [7]. Furthermore,
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modulates promoter methylation of the estrogen receptor
alpha and matrix metallopeptidase-2 and -9 genes in vas-
cular smooth muscle cells [8,9].
The present work analysed the effects of lipoprotein-
induced de novo DNA methylation on gene expression in
THP-1 macrophages. Furthermore, it tested the involve-
ment of individual DNA methyltransferase enzymes and
known DNA methylation-mediating pathways. Our find-
ings are discussed in the context of the current knowledge
on the role of native lipoproteins in epigenetic gene regu-
lation and inflammation.
Methods
Cell culture, lipoprotein isolation
THP-1 monocytes were differentiated to macrophages as
previously described [7]. For Oil Red O staining and intra-
cellular lipid determination, macrophages were processed
a sd e s c r i b e d[ 7 ] .H u m a nV L D L ,L D La n dh i g h - d e n s i t y
lipoprotein (HDL) were isolated and mixed to create the
VLR mix (concentrations in μg protein/ml: 68 VLDL, 32.1
LDL, 91.1 HDL) that was used to stimulate THP-1 macro-
phages in serum-free conditions for 24 h as previously
described [7]. The rationale for VLR composition is out-
lined in [7] and in brief is the following: 1) relative lipopro-
tein proportions reproduce a hyperlipidaemic profile
similar to the one observed in APOE-null mice and in dia-
betic patients; 2) final absolute lipoprotein concentrations
are ~10-fold lower than hyperlipidaemic levels to avoid
cell toxicity; 3) triglyceride-rich lipoprotein levels in VLR
were sufficient to induce intracellular lipid (Oil Red O-
stained) droplets in our conditions (not shown) and
increased intracellular triglyceride levels (additional file 1:
Figure S1), suggesting that THP-1 macrophages exposed
to VLR represented a model of lipid-loaded counterparts
observed in hyperlipidaemic atherosclerosis [1]. Each lipo-
protein preparation represented a pool of a variable num-
ber of donors with unspecified lipidaemic status, obtained
either in Malmö, Sweden (4 independent preparations) or
Mexico City, Mexico (3 independent preparations), as spe-
cified in the Results section for each experiment. Lipopro-
tein preparations were stored at -80°C for less than 6
months and used within 3 days of thawing.
Genome expression arrays
Affymetrix GeneChip Human Genome U133 Plus 2.0
Arrays were hybridized with labelled total RNA extracted
by using the RNeasy system (Qiagen), scanned with an
Affymetrix GeneChip Scanner 3000 according to standard
protocols at the microarray facility, Rigshospitalet, Copen-
hagen, Denmark. RNA integrity was checked by agarose
electrophoresis at the source laboratory and again at the
microarray facility. The dChip software (build April 15,
2005) was used for normalization and modelling using the
PM-only model. Array data were deposited in the GEO
database (http://www.ncbi.nlm.nih.gov/geo/) with acces-
sion numbers GSE9101 and GSM230349-GSM230360.
For pathway analysis, the BioCarta (http://www.biocarta.
com) and Reactome (http://www.reactome.org) databases
were searched with the modeled-based gene set analysis
(MGSA) that analyzes all categories at once by embedding
them in a Bayesian network in which gene response is
modelled as a function of the activation of the categories
[10,11]. Probabilistic inference is used to identify the active
categories. Pathways were selected if identified by both
databases and with p < 0.05.
Gene expression
For quantitative RT-PCR, one-tenth of cDNA obtained
from 1 μg total RNA was amplified by using the LightCy-
cler Fast Start DNA MasterPLUS SYBR green I system
(Roche) according to manufacturer’si n s t r u c t i o n si na
LightCycler 1.5 (Roche). Primer sequences were obtained
with qPrimerDepot (http://primerdepot.nci.nih.gov). Rela-
tive expression levels were calculated by subtracting the
average GAPDH CP from the CP of the target gene
obtained from the same cDNA and applying the formula
2
-ΔCP. CP values were calculated by the LightCycler 1.5
software. All samples were in triplicate. The primers used
are listed in additional file 2: Table S1. DNMT1 and -2
expression was analysed by RT-PCR with the following
oligonucleotides: 5’-AAGTAGAAGCGGTTGGGGCCG-3’
and 5’-GGCAGGCCCAATGAGACTGAC-3’ (DNMT1);
5’-ATGGAGCCCCTGCGGGTGCTG-3’ and 5’-GTGAAT
GGCTGGCAGGGAGGG-3’ (DNMT2). GAPDH cDNA
was used as loading control by using commercial oligonu-
cleotides (Clontech, Mountain View, CA). Immunoblot-
ting was performed using the antibody Abcam no.
ab14601 (Dicer) and the following Santa Cruz Biotechnol-
ogy products: sc-271729 (DNMT1), sc-365001 (DNMT2),
sc-20703 (DNMT3A), sc-20704 (DNMT3B), sc-20705
(DNMT3L), sc-7210 (a-actin). Positive controls were ES-2
cell lysate (Santa Cruz Biotechnology) for DNMT3L and
human Ficoll gradient-purified peripheral blood mononuc-
lear cells for other DNMTs and Dicer. ELISA kits were
used to detect IL-6 (R&D Systems, Abingdon, UK, cat.
D6050) and IL-23 p19 (eBioscience, San Diego, CA, cat.
88-7234) in cell supernatants according to manufacturer’s
instructions.
Global DNA methylation and histone posttranslational
modifications
Global DNA methylation, histone acetylation and
methylation levels were measured as described [7,12].
Gene-specific DNA methylation
For analysis of bisulfite-treated DNA, 1 μgD N Aw a s
modified with the EZ DNA Methylation-Gold™ system
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tions. One-tenth of modified DNA was amplified with
gene-specific primers listed in additional file 2: Table S1.
PCR products were either subjected to melting analysis
using LightCycler Fast Start DNA Master
PLUS SYBR
green I in a Light Cycler 1.5 machine (Roche) [13] or
sequenced (minimum 10 clones per studied sequence).
For combined bisulfite restriction analysis (COBRA),
bisulfite-modified DNA was digested with 1U TaqI or
BstUI/μg initial DNA and amplified with gene-specific
primers in the same Light Cycler system. For relative
quantification, the average mock sample CP was sub-
tracted from the CP of enzyme-treated triplicate samples
and the formula 2
-ΔCP was used. CP values were calcu-
lated by the LightCycler 1.5 software. All samples were in
triplicate.
Proteomics
For two-dimensional electrophoresis of nuclear proteins,
nuclei were purified essentially as described in Schreiber et
al. [14]. Protein electrophoresis was performed according
to standard protocols with first dimension separation per-
formed in a pH3-10 range. Spots were counted in silver-
stained gels by using an UMAX scanner and the Image-
Master™ 2D Platinum software (Amersham Biosciences,
Little Chalfont, UK) after correcting for background
according to manufacturer’s instructions. For kinomics
studies, an immunoblot-based Kinetworks™ Phospho Site
Screen (KPSS-4.1, Kinexus, Vancouver, Canada) was
employed. The manufacturer performed blotting, immu-
nodetection and data normalisation.
DNMT knockdown
At 48 h of differentiation, cells were transfected with
20 μM siRNA or carrier (controls) and siPORT Amine
(both from Ambion) according to manufacturer’s instruc-
tions for a 6-well plate format, in serum-free medium for
24 h, followed by a change to complete medium. At the
end of differentiation, cells were stimulated with VLDL for
24 h and collected by gentle scraping. Total siRNA incu-
bation thus amounted to 72 h. To validate our transfection
protocol, we performed pilot experiments with a FAM-
labelled siRNA (Ambion ID no. AM4622). Two DNMT1-
specific (Ambion ID no. 110915 and 110917, respectively)
and one DNMT2-specific (Ambion ID no. 111450) pre-
designed siRNAs were used. Cell viability was measured
by trypan blue staining.
Micro-RNA (miRNA) array
Total RNA was isolated and fractionated using methods
optimized for small RNA recovery and the resulting
miRNA fraction labelled and hybridized onto two colour
microarrays as described [15].
Results
Down-regulation of gene expression in VLR-stimulated
cells
Our previous data showed that VLR causes global DNA
hypermethylation [7]. VLR-induced de novo DNA methyla-
tion might target a combination of gene promoters and
gene body sequences, presumably causing mainly tran-
scriptional repression in the former case and sustained or
enhanced transcription in the latter [16,17]. Reasoning that
a general transcriptional repression should be observed if
promoters are a major target of VLR-induced de novo
DNA methylation, we conducted a genome expression
array analysis (Affymetrix GeneChip Human Genome
U133 Plus 2.0 array) to compare control and VLR-stimu-
lated cells. In this and all experiments indicated below, sti-
mulations were carried out for 24 h. Three independent
lipoprotein preparations obtained in Sweden were analysed,
each in triplicate. Counting triplicate controls, the experi-
ment amounted to 12 individual arrays. Clustering analysis
of all genes showed an excess of down-regulated tran-
scripts compared to up-regulated ones in VLR-stimulated
cells, and consistence across lipoprotein preparations
(Figure 1A). All subsequent gene expression analyses pre-
sented here were conducted on transcripts showing a > 3-
fold change in expression with a P < 0.001 (ANOVA test)
in all three lipoprotein preparations compared to controls.
Genes that were down-regulated by VLR were 3.2-fold
more abundant than up-regulated ones (70 vs. 22, respec-
tively) (additional file 3: Table S2). The sum of differences
in RNA expression between VLR-stimulated and control
cells averaged for the three lipoprotein preparations was
47,335.8 and 8,435.1 for down- and up-regulated genes,
respectively, representing a 5.6-fold excess of transcripts
down-regulated by VLR compared to up-regulated ones.
Interestingly, a serendipitous finding suggested that cor-
responding effects were detectable at the proteome level.
As part of a parallel project assessing the impact of VLR on
nuclear protein expression, we performed two-dimensional
electrophoresis of nuclear proteins in two independent
experiments using one lipoprotein preparation obtained in
Sweden and independent from the ones used for expres-
sion arrays. The results revealed a 24-44% reduction in
total spot count in VLR-treated compared to control cells
(1,723 vs. 2,258 and 1,339 vs. 2,409 spots in the two experi-
ments; data not shown). These observations, although lim-
ited to an incomplete sample of the whole genome, are
consistent with the idea that a global decrease in gene
expression is expected to result in a decrease in translation.
Identity and independent validation of genes down-
regulated by VLR
Pro-inflammatory genes (IL1B, IL6, IL7R, IL23A), genes
participating in inflammatory responses (IRAK2, PTX3,
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Page 3 of 12TRAF1) [18-21] and cholesterol transport (ABCG1) were
pronouncedly down-regulated by VLR (Table 1; gene
symbols will be used throughout the text, for corre-
sponding gene names see additional file 3: Table S2).
IL23A and IL1B RNA showed a > 20-fold repression
and ranked first and third, respectively, among down-
regulated genes. Other down-regulated genes included
members of chemokine, metallothionein and Zn/cation
transporter families. By contrast, genes up-regulated by
VLR were a more heterogeneous group. VLR did not
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Figure 1 Effects of VLR on gene expression. A, all-gene expression clustering in VLR-stimulated THP-1 macrophages compared to controls - i.
e. no VLR - following a 24 h-challenge. VLR1-VLR3, individual lipoprotein preparations, each in triplicate. Blue and red, relatively down- and up-
regulated genes, respectively. Clustering shows consistent differences between control and VLR-stimulated cells. Notice the excess of VLR-down-
regulated genes compared to up-regulated ones. B, validation of array gene expression data by ELISA for IL-6 and IL23 p19 (indicated with gene
symbol IL23A for simplicity; data are indicated as ng/ml/10
6 cells) and by qRT-PCR (graphs below ELISA values). Genes are ordered according to
the functional grouping criteria of Table 1. qRT-PCR y-axis values are 2
-ΔCP in comparison with the average of the GAPDH CP triplicates. Black
bars, control; white bars, VLR-stimulated. Bars, standard deviations. P < 0.05 in all cases.
Table 1 Characteristics of genes down-regulated by VLR
Function Gene symbol
Inflammation IL1B, IL6, IL7R, IL23A, IRAK2, PTX3, TRAF1
Cholesterol transport ABCG1
Chemotaxis CCL2, CCL3, CCL4, CCL8, CCL20, CXCL6, CCR7
Solute carrier family (Zn, cation transport) SLC7A2, SLC39A8, SLC39A14
Metal binding, control of oxidative stress gb:AL031602 (MT1E-like) MT2A, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X,
Matrix metalloproteinase MMP1
Cell adhesion CADM1
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related genes, in accordance with our earlier biochem-
ical and cellular morphology data (additional file 3:
Table S2) [7]. Accordingly, pathway analysis according
to the BioCarta and Reactome databases consistently
indicated that chemotaxis (CCR5-mediated, enrichment
score (ES) = 0.47, p = 0.011), inflammation (IL1R-
mediated, ES = 0.30, p = 0.006) and Zinc transport
(solute carrier 39 (SLC39) family-mediated, ES = 0.14,
p = 0.005) pathways were significantly down-regulated
in VLR-stimulated cells compared to controls.
For array data validation, cells were stimulated with a
pool of 3 independent lipoprotein preparations obtained
in Mexico. Array expression data were confirmed by
ELISA (IL-6, IL-23 p19) and qRT-PCR (the latter 2 genes
and 19 additional genes) (Figure 1B). We used GAPDH as
reference transcript as its expression was not affect by
VLR, as assessed by whole genome expression array data
(not shown). All genes showed a significant (P < 0.05)
decrease in expression. As control we used BTF3,r a n -
domly chosen among genes whose expression levels were
not significantly changed by VLR in either expression
microarrays or validation qRT-PCR (not shown).
Promoter methylation status of genes down-regulated by
VLR
The general transcriptional repression induced by VLR
suggested that promoters are major targets for de novo
DNA methylation by this lipoprotein mixture. Thus,
selected expression-validated genes belonging to relevant
functional groups (inflammation, cholesterol transport,
metallothioneins, see Table 1; 12 genes total) were first
screened for promoter methylation status by melting analy-
sis. DNA extracted from an aliquot of the same cells used
for gene expression validation (see previous paragraph) was
used. Results showed hypermethylation in VLR-treated
cells compared to controls in all cases but for the choles-
terol transporter ABCG1 and the control gene BTF3 (not
shown). The same genes were subsequently analyzed by
COBRA (10 genes) or bisulfite modified DNA sequencing
(2 genes) to assess whether that increase in methylation
was significant. Our COBRA analysis can detect significant
changes in DNA methylation, although it cannot yield
absolute levels. All genes but ABCG1 showed significant (P
< 0.05) promoter hypermethylation in VLR-treated cells
compared to controls (Figure 2A,B).
Gene mapping revealed that 41 of the 70 down-regu-
lated genes (or ~59%) were found in clusters on chromo-
somes, i.e. in groups of 3 or more genes per chromosome
arm (additional file 4: Table S3). This gene distribution
was significantly different from a random one (P <
0.00003, Chi-square test). The expected number of genes
per chromosome in a random distribution was calculated
correcting for chromosome size http://www.ncbi.nlm.nih.
gov/guide/genomes-maps/. In one case, 7 down-regulated
metallothionein genes clustered in a 1 Mb portion of 16q.
Another noticeable example was the down-regulation of a
group of chemokine and Zn/cation transporter genes
belonging to 3 distinct clusters in 4q, 8p and 17q. Further-
more, the inflammatory genes IL6, IL1B and PTX3 were
included in clusters (additional file 4: Table S3). No such
clustering was observed among up-regulated genes.
Effects of individual lipoproteins on de novo DNA
methylation and histone modifications
In order to assess which lipoprotein species of VLR are
most active in inducing de novo DNA methylation and
histone modifications, we stimulated cells with increasing
amounts of each individual lipoprotein up to the highest
dose used in VLR - i.e.9 1 . 1μg protein/ml HDL - for 24 h.
One of the three lipoprotein preparations obtained in
Mexico were used. Both VLDL and LDL induced a signifi-
cant de novo DNA methylation with relative potency
VLDL > LDL, or a 17% and 10% increase in DNA methy-
lation, respectively, compared to control (Figure 3A).
Noticeably, the effect of HDL if any, was a marginal DNA
hypomethylation. The response to HDL was not due to a
biphasic time-course, since global DNA methylation did
not vary across the 0-24 h. interval in macrophages chal-
lenged with each lipoprotein at 91.1 μgp r o t e i n / m lc o n -
centration (Figure 3B). Histone post-translational
modification analysis revealed a distinct specificity in the
responses to lipoproteins. VLDL only induced an increase
in H4K20 hypermethylation, whereas HDL only caused a
loss of acetylated H4 (40% increase and 15% decrease,
respectively, compared to control cells) (Figure 3C,D).
Neither histone modification was significantly affected in
LDL-stimulated cells.
DNMT1 mediates VLDL-induced de novo global and gene
promoter DNA methylation
Mammalian DNA methylation is performed by a family of
DNA methyltransferases (DNMTs) of which the best char-
acterised are DNMT1, -2, -3A, -3B and -3L. DNMT1 is
considered to be the canonical maintenance DNMT, i.e.
the enzyme that copies pre-existing DNA methylation pat-
terns during replication, whereas de novo DNMT activity
is largely attributed to DNMT3A and -3B [22,23]. On the
other hand, DNMT3L is enzymatically inactive and coop-
erates with DNMT3A to direct DNA methylation of
sequences containing specific histone post-translational
modifications, while RNA methylation is probably a dis-
tinctive biological activity of DNMT2 [24-26].
The four independent sets of genome expression arrays
each conducted in triplicate for a total of 12 individual
arrays presented in the whole genome expression array
experiment (see above) consistently indicated that THP-1
macrophages express DNMT1 and -2, but not DNMT3A,
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with VLR or unstimulated (Figure 4A). The presence of
DNMT1 and -2, and absence of DNMT3A and -B were
confirmed by RT-PCR (using the same pool of lipopro-
teins prepared in Sweden for the microarray experiment;
not shown) and immunoblot (using the same pool of
material produced in Mexico as used for microarray vali-
dation; Figure 4B). The apparent increase in DNMT1
expression in VLR-stimulated cells did not exceed 25%
compared to control, when normalized by a-actin levels.
Therefore, expression data suggested that either DNMT1
or DNMT2 or both mediate VLDL -induced de novo
DNA methylation in THP-1 macrophages. To assess the
relative contribution of DNMT1 and -2 in VLDL-induced
de novo DNA methylation in THP-1 cells, we employed
an RNAi-mediated knockdown approach. One of the lipo-
protein preparations obtained in Mexico, different from
the one used to assess responses to individual lipoproteins
(see above) was used in this case. siRNA treatment low-
ered DNMT expression to undetectable levels in our RT-
PCR conditions (Figure 5A). Two distinct DNMT1-specific
siRNAs abolished VLDL-induced de novo DNA methyla-
tion and promoter hypermethylation of the VLR-downre-
gulated genes IL6 and IL1B, whereas a DNMT2-specific
siRNA had no significant effect (Figure 5B,C). DNMT1
knockdown did not result in any change in cell viability
compared to controls (not shown) in contrast with pre-
vious data obtained in HeLa cells, thus suggesting that the
effects of DNMT1 knock-down are cell type-specific [27].
We attempted to complement the RNAi approach with
re-expression of a siRNA-insensitive DNMT1 RNA, but
pilot transient expression experiments using lipofectamine
and an empty vector (pcDNA, Invitrogen) failed, likely due
to the inability of THP-1 macrophage to survive multiple
transfections during differentiation. Furthermore, to
explore possible signalling pathways mediating DNMT1
activation by VLDL, we employed an immunoblot-based
kinomics analysis of the phosphorylation status of 45
kinase substrates. These experiments were conducted with
the lipoprotein preparation obtained in Sweden and used
in DNMT RT-PCR experiments (see above, this para-
graph). Results were representative of a pool of three
A
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Figure 2 Methylation analysis of VLR-regulated genes. A and B, COBRA and bisulfite-modified DNA sequence analysis, respectively. A, values
on the y-axis are 2
-ΔCP in comparison with the average of mock digestion triplicates. An increase in methylation results in relatively low 2
-ΔCP
values. Black bars, control; white bars, VLR-stimulated. Bars, standard deviations. B, numbers on the vertical axis indicate the position of the
analyzed sequence relative to the transcription start site (bp). Ticks represent CpG dinucleotides. Horizontal bars represent the extent of
methylation of the corresponding residues in the clones analyzed.
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normalization and considering only > 2-fold differences,
VLDL produces small changes, as it decreased protein
kinase C zeta (PKCzeta) T410 phosphorylation by 3.4-fold,
and marginally increased baseline v-raf-1 murine leukemia
viral oncogene homolog 1 (Raf-1) S259 phosphorylation
(2-fold; Figure 5D). Since T410 phosphorylation is an acti-
vating modification of PKCzeta, our preliminary data sug-
gest that VLDL decreases PKCzeta signalling, whether by
inhibiting phosphorylation and/or expression of that sig-
nalling factor [28].
Involvement of miRNAs and Dicer
Among factors guiding DNMTs to their targets, the Dicer
and micro-RNA (miRNA) pathway seems to play a pivotal
role at least in some cell types, as genetic evidence shows
that Dicer is necessary to maintain the non-permissive
state of selected genomic regions at least in some cell
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maturation of miRNAs, a class of endogenous small non-
coding RNAs known to control gene expression at the
post-transcriptional level. In addition to the latter func-
tion, miRNAs and other Dicer substrates direct DNA
methylation to specific sequences in various organisms
including mammals [31,32].
To explore the hypothesis that VLDL causes de novo
DNA methylation by inducing the expression of specific
miRNAs or other Dicer substrates capable to direct
DNMT1 to specific targets, we undertook a miRNA
expression analysis. In addition, we examined the expres-
sion levels of Dicer in THP-1 macrophages. A pool of 2 of
the lipoprotein preparations obtained in Sweden and used
in the whole genome microarray experiment was used.
miRNA expression microarrays showed that VLDL had
marginal effects on miRNA expression levels, as following
array global centered normalization, no significant miRNA
differential expression - i.e. > 2-fold - was detected in two
independent biological replicates. As for Dicer expression,
whole genome expression arrays yielded mixed indica-
tions, as only 3 of the 5 DICER1 probes were scored as
“present”. Nonetheless, RT-PCR (not shown) and immu-
noblotting (conducted with distinct cellular and lipopro-
tein material in Scandinav i aa n dM e x i c o ;F i g u r e4 B )
revealed that Dicer (DICER1 g e n e )w a sn o te x p r e s s e di n
lipoprotein-stimulated or control THP-1 macrophages.
Therefore, our data provide evidence that VLDL-induced
de novo DNA methylation is not a Dicer-mediated process
in THP-1 macrophages.
Discussion
The present work shows that VLR, a human native VLDL-
and LDL-rich lipoprotein mix, induces a net global
decrease in gene expression that mirrors the previously
reported global de novo DNA methylation caused by VLR
in THP-1 macrophages [7]. Proteome data independently
support these findings, although the effects of VLR were
more prominent on protein species than on transcripts.
This observation points to VLR affecting a combination of
DNMT3A
DNMT3B
DNMT3L
DICER1
α-actin
VLDL
VLR
Control
Pos. control
Gene symbol   Control  VLR1  VLR2  VLR3  average normalized
      intensity
DNMT1    PPP PPP PPP PPP          576.41
DNMT2    PPP PPP PPP PPP       100.01
DNMT3A  AAA AAA AAA AAA           37.39
DNMT3B  AAA AAA AAA AAA           35.98
DNMT3L  AAA AAA AAA AAA           23.03
ATP6VOC  PPP PPP PPP PPP    1,230.35
APOB    AAA AAA AAA AAA           31.03
A
B
DNMT1
DNMT2
VLDL
VLR
Control
α-actin
Figure 4 Expression of DNMTs and DICER1 in THP-1 macrophages. A, Affymetrix present/absent calls (P and A, respectively) and average
normalized probeset intensity are shown for arrays (grouped in triplicates) addressing the effects of VLR. ATP6VOC and APOB are included as
examples of a highly expressed and silent gene, respectively. VLR1 through VLR3, independent VLR preparations. B, Immunoblot analysis of
DNMT and DICER1 expression. VLDL was used at 91.1 μg protein/ml concentration. Representative alpha-actin immunoreactivity using peripheral
blood mononuclear cells as positive control is shown.
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Page 8 of 12translation repression, post-translational modification reg-
ulation and nuclear protein stability. VLR-induced tran-
script down-regulation includes pathways involved in
fundamental macrophage functions such as inflammation,
chemotaxis, metal and cation transport. The down-regula-
tion of pro-inflammatory genes is a prominent effect of
VLR. Seven pro-inflammatory genes are repressed, in addi-
tion to one solute carrier gene (SLC7A2) that participates
in macrophage activation by various cytokines [33].
Although apparently in contrast with data showing athero-
genic effects of VLDL, these distinct effects of VLR are
consistent with existing literature indicating that stimula-
tion by native VLDL per se results in a weak, if any,
inflammatory response in cell culture models [34]. For
example, VLDL induces inflammatory marker expression
only in synergy with cytokines in human aortic endothelial
cells and macrophages [35-37]. Similar results were
obtained in a side-by-side gene expression analysis in
THP-1 macrophages stimulated with oxidised LDL, or oxi-
dised or native chylomicrons remnants. Oxidised LDL and
oxidised chylomicrons produced a radically different gene
expression pattern from the one induced by native chylo-
microns, including a down-regulation of ABCA1 by the
latter, resembling the effects of VLR on ABCG1 presented
here [9,38]. Furthermore, native LDL is a poor activator of
the NLRP3 inflammasome, a protein complex involved in
IL-1beta production, compared with corresponding oxi-
dised versions [39]. Based on our results and supported by
evidence discussed above, we conclude that VLR-induced
de novo DNA methylation in THP-1 macrophages does
not reflect a pro-atherogenic response as our earlier data
seemed to indicate [7], rather it underlies an anti-inflam-
matory response. It is possible that in normal physiological
conditions circulating native VLDL and possibly other
VLDL (μg protein/ml)
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D
Figure 5 DNMT1 mediates VLDL-induced de novo DNA methylation. A, RT-PCR analysis of DNMT expression in siRNA-treated cells
stimulated with two preparations of VLDL at 58 μg protein/ml. B, effects of siRNA-mediated knockdown of DNMT1 or DNMT2 on total 5 mdC
content. Solid squares, control; open squares, DNMT2-specific siRNA; solid diamonds, DNMT1-specific siRNA ID no. 110915; open diamonds,
DNMT1-specific siRNA ID no. 110917 (both from Ambion). Asterisks indicate statistically significant comparisons between siRNA-treated and
control cells. For simplicity, when cells treated with either DNMT1-specific siRNA show different significance levels, only the lower one is shown
(*, P < 0.05; ***, P < 0.001). C, effects of siRNA treatment on the methylation status of IL6 and IL1B, as assessed by COBRA. DNAs from the two
DNMT1-specific siRNAs were pooled for this analysis. Statistical significance is indicated as in B. Bars, standard deviations. D, VLR alters baseline
phosphorylation of PKC zeta and Raf-1. Fields of Kinexus Kinetworks™ Phospho Site Screen KPSS-4.1 containing PKC zeta T410 and Raf-1 S259 in
control and VLR-stimulated cells. Raf-1 migrates as multiple bands reflecting multiple phosphorylation states [55]. Positions of relevant MW
standard are shown on the left (kDa).
Rangel-Salazar et al. BMC Genomics 2011, 12:582
http://www.biomedcentral.com/1471-2164/12/582
Page 9 of 12lipoproteins buffer macrophage functions by limiting pro-
inflammatory gene activity. The observation that exogen-
ous lipoproteins can protect against endotoxin-induced
death and decrease plasma TNF in vivo provides ground
to this idea [40]. On the other hand, when pro-inflamma-
tory signals are present presumably above a critical thresh-
old, particularly in association with lipoprotein oxidation,
or act chronically as in sustained hyperlipidaemia, anti-
inflammatory gene regulation mechanisms would be over-
run. As a consequence, native lipoproteins cease to exert
negative controls on macrophage function and indeed act
as an activating switch by synergising with inflammatory
factors. Persson and co-workers discussed this basic idea
in detail [37].
For all analyzed genes but ABCG1, VLR-induced silen-
cing is associated with de novo DNA methylation at the
corresponding promoter. Interestingly, the non-random
distribution of down-regulated genes suggests that VLR
regulates gene expression by a coordinated mechanism
resembling instructive epigenetic regulation reported in
cancer [41].
In addition, our results are in apparent contrast with
published data suggesting that DNA hypermethylation
may underlie a pro-inflammatory response in some condi-
tions [42]. Our data complement the latter observations,
by showing that DNA hypermethylation is not invariably
associated with inflammation. Rather, we suggest that spe-
cific epigenetic modifications are imposed on distinct sets
of sequences in a stimulus-specific fashion thus inducing
specific gene expression patterns, although the resulting
global epigenetic parameters - i.e.t o t a lg e n o m eD N A
methylation level - may be similar.
Furthermore, we observed a potentially interesting selec-
tivity in de novo DNA methylation and H4K20 hyper-
methylation responses between individual lipoprotein
species. Our data indicate that the response to VLR must
be the sum of activities of factors specific for or present at
different amounts in each lipoprotein species. The
mechanisms underlying the observed differential effects on
histone post-translational modifications are currently
unknown and deserve investigation. Clearly, understand-
ing the mechanisms by which lipoproteins modulate chro-
matin structure in macrophages and other cell types
requires a detailed screening of lipoprotein components.
The observation that lipoprotein preparations from Swe-
den or Mexico produced consistent effects in whole gen-
ome expression array analysis and its validation, suggests
the preliminary conclusion that the factor eliciting the
responses described here is a structural lipoprotein com-
ponent probably not qualitatively or quantitatively affected
by diet. Interestingly, recent evidence shows that palmitic
acid, an abundant pro-inflammatory fatty acid of endogen-
ous and dietary origin, promotes global DNA hypermethy-
lation in primary human myocytes [43].
As for the identity of intracellular factors mediating
VLDL-induced de novo DNA methylation, the absence of
the canonical de novo DNMTs DNMT3A and -3B was
unexpected in THP-1 macrophages. Our data indicate
that DNMT1 is necessary and sufficient for de novo DNA
methylation in response to VLDL, in contrast with its
widely accepted role as canonical maintenance DNMT.
Interestingly, these observations are supported by our pre-
liminary kinome data showing that VLDL lowers the cellu-
lar levels of T410-phosphorylated - i.e. active - PKCzeta,
which has been recently shown to inhibit DNMT1 [44].
Previous studies demonstrated that DNMT1 might partici-
pate in de novo DNA methylation in cooperation with
DNMT3A and -3B [45,46]. Accordingly, exogenous
DNMT1 expression induced de novo methylation of a
relatively small number of genes in HEK-293T cells, possi-
bly in cooperation with endogenous DNMT3A/3B [47].
To our knowledge, the only previous example of an inde-
pendent de novo methylation activity for DNMT1 is the
demonstration that this enzyme re-establishes somatic
patterns of non-CpG methylation following their erasure
in the germline [48]. The present study provides new evi-
dence that DNMT1 can perform de novo DNA methyla-
tion independently of maintenance DNMTs. A de novo
activity for DNMT1 may be physiologically relevant in tis-
sues in which an age-related decline of DNMT3A/B
expression has been documented [49,50]. Interestingly,
D N M T 1m i g h tb eas p e c i f i cm e d i a t o ro fde novo DNA
methylation in response to pro-inflammatory signals, as
IL-6 induces upregulation and nuclear translocation of
DNMT1 [51-53]. As for DNMT2, the absence of any
effects of this DNMT on DNA methylation confirms pre-
vious literature data [25].
In addition, our data provide genetic evidence on the
involvement of the Dicer pathway in epigenetic responses
to VLDL. Taken together, the absence of Dicer expres-
sion and the lack of any effect of VLDL on miRNA pro-
duction demonstrate that the latter factors or other small
non-coding RNAs generated by Dicer do not mediate
VLDL-induced de novo DNA methylation in THP-1
macrophages. These observations indicate that chromatin
regulation by Dicer-mediated pathways if present in
mammals, is confined to specific cell types rather than
being a universal mechanism. Nonetheless, it is possible
that Dicer-independent RNA-mediated DNA methylation
operates in THP-1 cells as reported in plants [54].
Conclusions
We provide insights into gene targets and potential
mechanisms for native lipoprotein-induced epigenetic
gene regulation in THP-1 macrophages. These findings
contribute to understanding interactions between the
genome and lipids or other lipoproteins components in
health and disease. Furthermore, by studying candidate
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Page 10 of 12factors involved in epigenetic responses to lipoproteins,
we provide new evidence that the canonical maintenance
DNMT1 is capable of de novo DNA methylation activity,
and show proof of principle that the Dicer pathway is not
indispensable for de novo DNA methylation in all human
cells.
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Additional file 1: VLR increases intracellular lipids in THP-1
macrophages. Quantification of intracellular triglycerides and cholesterol
in VLR-stimulated THP-1 macrophages. Black and grey bars, triglycerides
and cholesterol, respectively. ***, P < 0.005. Data are presented as
average and s.d. of triplicates of one experiment.
Additional file 2: Primers used in the study. List of gene-specific
primers used for RT-PCR and DNA methylation analysis.
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control cells, left column). Notice the excess of negatively regulated
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transcripts are represented on arrays more than once.
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